Chimeric: Media Thread, page-775

from the newsletter

In preparation for the potential move to a Phase 2 trial for our
CHM CLTX CAR-T technology targeting recurrent / progressive
glioblastoma, the team continues to prepare to expand the Phase 1B
trial at Sarah Canon Cancer Centre in Texas (NCT05627323).Based
on advice from our experts we are in the process of making some
adjustments to the way the CLTX CAR-T is delivered

Rebecca is impressive, no mucking around. Thought Jen was the best, Rebecca seems easily topping her.

GLTA